CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Edesa Biotech, Inc. (EDSA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Edesa Biotech, Inc. (EDSA)

Pharmaceutical Preparations · market cap $38M · as of 2026-07-15

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-11 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Edesa Biotech (EDSA) is a micro-cap clinical-stage pharmaceutical company with 17 employees and a $61M market cap, built around a single Phase 2 asset: EB01 Cream 0.2% for Allergic Contact Dermatitis. The company holds $10M in cash (~7.3 months runway) and carries no revenue, making near-term financing essentially inevitable. The next scheduled event is an earnings release on 2026-08-14.
The catalyst path
  • 2026-12-11 (est.)Earningsimp 5/10
Pipeline
AssetPhaseIndication
EB01Phase 2Allergic Contact Dermatitis
vilobelimabPhase 2Acute Respiratory Distress Syndrome (ARDS)
paridiprubartPhase 2Acute Respiratory Distress Syndrome (ARDS)
EB06Phase 2Non-Segmental Vitiligo (NSV)
Price & technical context
3-month
-54.5%
6-month
-80.9%
12-month
+15.6%
52-wk range
$0.80–$18.28
vs 50-day MA
-33.9%
vs 200-day MA
-65.0%
Realized vol
168.2%
Max drawdown
-89.7%

Daily closes through 2026-11-20. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for EDSA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.